Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

Defeat Duchenne Family Forum – Montréal

Registration is now open for the Defeat Duchenne Family Forum taking place on Saturday, May 2, 2020, in Montréal, Québec at Shriners Hospitals for Children – Canada. Presented by PTC Therapeutics and in partnership with La Force DMD, this unique educational event provides the opportunity for you – families and caregivers navigating the Duchenne journey, to come […]


New Neuromuscular Network for Canada

Jesse’s Journey is proud to represent the Duchenne community in the new neuromuscular network for Canada, NMD4C (NMD for Canada). The neuromuscular network for Canada brings together the country’s leading clinical, scientific, technical and patient expertise to improve care, research and collaboration in neuromuscular disease. Launched in January 2020 with funding from the Canadian Institutes of Health […]


Celebrate Past – Ignite New Vision

2020 is an exciting year for Jesse’s Journey as we celebrate our past and ignite a bold new vision for our future. This year marks the 25th anniversary of the organization as our founder, John Davidson, set out on an incredible mission to push his son, Jesse, across Ontario in his wheelchair – a trek of 3,339 […]


Sarepta Therapeutics Announces Partnership with Roche

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 “…Sarepta and Roche have entered into a licensing agreement that would provide Roche exclusive rights to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) outside of the United States. As a mission-driven organization committed to families impacted by […]


Jesse’s Journey Provides Game-Changing Grant Towards Therapeutic Trial

Jesse’s Journey is proud to announce its gift of $300,000 towards a breakthrough clinical trial, which may empower local researchers to discover a therapeutic solution to the degenerative disease Duchenne muscular dystrophy. The clinical trial is building upon promising Phase I research involving myoblast transplantation. This therapeutic approach applies to all Duchenne patients, independently of […]


New Year Update from Santhera Pharmaceuticals

Santhera Pharmaceuticals have shared their January update.    “Our main focus in the U.S. in the first half of the year is to bring the SIDEROS clinical trial to full enrollment and we ask the community’s help, now more than ever, to achieve this goal. The SIDEROS clinical trial, which investigates the safety and efficacy […]


Inaugural Defeat Duchenne Family Forum in Western Canada a Huge Success

More than 75 Canadians came together for the inaugural Defeat Duchenne Family Forum presented by PTC Therapeutics on Saturday, November 2, 2019, in Calgary, Alberta. Families from across Western Canada affected by Duchenne muscular dystrophy came together with world-renowned researchers, clinicians, and industry professionals for a day of education, inspiration, and hope. Read more here.


Double The Impact of Your Gift

Unless you’ve experienced it for yourself, it’s nearly impossible to understand the ramifications of finding out your loved one has Duchenne muscular dystrophy. Jesse’s Journey is lucky to have the support of families who are brave enough to share their stories because they know it’s the only way we can hope to inspire understanding and […]


Vamorolone Extension Trial Supports Muscle Gains in DMD with Fewer Side Effects, Topline Data Show

Vamorolone, an experimental treatment for Duchenne muscular dystrophy (DMD) being developed by ReveraGen Biopharma, continues to improve muscle function in DMD patients with fewer side effects than standard corticosteroids, topline data in 23 boys in an ongoing Phase 2 trial show. These findings were detailed in a late-breaking presentation by Eric Hoffman, PhD, chief executive […]


Edasalonexent Slows DMD Progression in Phase 2 Trial

Phase 2 study results of edasalonexent, an investigational oral small molecule NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD), suggest that the therapy is associated with slowed disease progression, as well as a good safety profile over the course of more than 50 patient-years of exposure in boys with the disease.1 Treatment with […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.